Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10%

Immunic, Inc. (NASDAQ:IMUX) is 1 of the stocks nether $1 that volition explode.

An array of pharmaceutical pills with the company's logo connected the bottle.

Immunic, Inc. (NASDAQ:IMUX) has precocious demonstrated beardown stock terms momentum, with its shares up 24.10% successful the past 5 days arsenic of the marketplace unfastened connected January 9, 2026.

Amid the stock terms surge, the company’s absorption reviewed 2025 show and outlined upcoming milestones, issuing a property merchandise connected January 7, 2026.

The institution reflected connected advancement crossed some neurologic and gastrointestinal programs, with CEO Dr. Daniel Vitt emphasizing completion of enrollment successful the duplicate Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium (IMU-838) successful relapsing aggregate sclerosis (RMS). Enrollment randomized 1,121 and 1,100 patients crossed much than 100 sites successful 15 countries. Management highlighted a synchronized top-line readout to measure the therapy’s imaginable to modify illness progression by combining neuroprotective Nurr1 activation with selective DHODH inhibition. The readout is expected by the extremity of 2026.

Meanwhile, durable disablement extortion was confirmed by semipermanent Phase 2 EMPhASIS information successful relapsing-remitting MS (RRMS). Over 92% of patients remained escaped of 24-week confirmed disablement worsening aft up to 5.5 years. A favorable information illustration was besides reported.

On the different hand, information from the Phase 2 CALLIPER proceedings successful progressive MS showed statistically important reductions successful 24-week confirmed disablement worsening (24wCDW) and accordant trends crossed subtypes. The results enactment neuroprotective effects autarkic of inflammation.

Management besides discussed IMU-856, an orally disposable and systemically acting tiny molecule modulator that targets Sirtuin 6 (SIRT6). The modulator showed promising aboriginal objective and preclinical signals for gastrointestinal obstruction restoration and value management. With this, the institution looks to grow its oral immunology portfolio connected the backmost of beardown financing successful 2025, including a $65 cardinal nationalist offering, providing resources to beforehand these programs.

Immunic, Inc. (NASDAQ:IMUX) is focused connected processing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases, including aggregate sclerosis, ulcerative colitis, and Crohn’s disease.

While we admit the imaginable of IMUX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.